BioNTech and Fosun Pharma, two pharmaceutical companies, created the joint venture. Under the terms of the agreement, Fosun Pharma and BioNTech will work jointly on the development of BNT162 in China, conducting clinical trials by leveraging Fosun Pharma’s extensive clinical development, regulatory, and commercial capabilities in the country.